Lead investigator: Dr Martina Finetti, Newcastle University
Funded by CCLG
Funded July 2018
Award: £10,079.00
Malignant rhabdoid tumours (MRT) are aggressive, frequently lethal tumours of early childhood and infancy. Current treatments (surgery, chemotherapy and radiotherapy) are often ineffective and cause harmful long‐term effects. MRT’s are caused by a mutation in a single gene named SMARCB1, despite having a stable genome they show abnormal development. This project aims to identify differences in MRT’s by using cutting‐edge single cell sequencing approaches. Analysing tumours at the single cell level will enable us to identify cell subpopulations within the same tumour and reveal the changes that occur in cells with this SMARCB1 mutation. We hope that this will allow us to identify possible effective new targets for treatment.